

**Glyn Stacey PhD, National Institute for Biological Standards and Control (NIBSC-HPA) .**

Glyn Stacey's is the Head of the Division of Cell Biology and Imaging at NIBSC and is Director for the UK Stem Cell Bank funded by the Medical Research Council and BBSRC. His scientific background has been in microbiology and cancer research. He has established special interests and activities in the field of cell biology relating to cell culture, safety issues and standardization. This has also lead to involvement in a range of related areas including plant tissue culture, cell preservation and management of biological resource centres. From 1989-1998 he worked at the Centre for Applied Microbiology and Research where he was involved in developing cell culture and cell banking procedures and established a cell biology research unit working on the development of cell substrates for manufacture of medical products and cell-based diagnostic assays. At NIBSC he has developed a broad remit on cell biology issues relevant to the quality and safety of new biological medicines and therapies based on the use of human and animal cells. In addition to developing a research portfolio in this area, he has also acted as an advisor to the UK Department of Health and the World Health Organization and has been a key member of working groups which have drafted national codes of practice and national and international regulatory guidance in cell-based medicine and use of cell substrates for manufacture of biologicals. He has coordinated national standards forums for bone marrow and cord blood transplant laboratories and currently coordinates the International Stem Cell Banking Initiative funded by a consortium of funding agencies from 20 countries. He also the chaired the Scientific Advisory Board of Stem Cells for Safer Medicine (a Govt/Pharma collaboration to establish stem cell-derived human models for toxicology). Glyn's work at NIBSC has invadved the creation of a series of clean-room facilities designed to operate under GMP for cell banking, and most recently completed the establishment of a new and expanded GMP facility with hotel laboratories for the development of clinical grade material which is now undergoing validation.